Authors
Katie Bechman, Sujith Subesinghe, Sam Norton, Fabiola Atzeni, Massimo Galli, Andrew P Cope, Kevin L Winthrop, James B Galloway
Publication date
2019/10/1
Source
Rheumatology
Volume
58
Issue
10
Pages
1755-1766
Publisher
Oxford University Press
Description
Objectives
To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid arthritis patients receiving JAK inhibitors.
Methods
We conducted a systematic literature review and meta-analysis of phase II and III randomized controlled trials of tofacitinib (5 mg bid), baricitinib (4 mg od) and upadacitinib (15 mg od). Patient-exposure years were calculated. A per-protocol analysis was applied, incorporating follow-up time from patients randomized to placebo who cross into the treatment arm. Pooled incidence rates per 100 person-years of SI and HZ were calculated. Incidence rate ratios (IRRs) of drug vs placebo were compared using a meta-synthesis approach.
Results
Twenty-one studies were included in the meta-analysis; 11 tofacitinib (5888 patients), six baricitinib (3520 patients) and four upadacitinib studies (1736 patients). For SI, the …
Scholar articles
K Bechman, S Subesinghe, S Norton, F Atzeni, M Galli… - Rheumatology, 2019